<DOC>
	<DOCNO>NCT00405639</DOCNO>
	<brief_summary>The follow do screen procedure determine patient eligible study : blood count , kidney liver blood test . Patients complete 6-minute walk test . Patients instruct follow no-added-salt diet 1-3 week study whole duration study . Diet instruction give patient patient collect his/her urine 24 hour active study day . Patients need avoid strenuous exercise abstain smoking , alcohol , caffeine 3 day prior study day . Patients remain regular medication .</brief_summary>
	<brief_title>Human B-type Natriuretic Peptide ( BNP ) ( Nesiritide ) Help Heart , Kidney , Hormonal Functions Persons With Lower Heart Pumping Function</brief_title>
	<detailed_description>Participants study randomize receive BNP placebo ( inactive , saline shot ) . The participant need give shot stomach ( similar diabetic give insulin ) twice day twelve week . The study require screen visit determine eligibility discus study . At visit blood draw heart liver function six minute walk do . There also two outpatient visit two inpatient stay , 48 hour , General Clinical Research Center ( GCRC ) St. Marys Hospital . During two in-patient stay GCRC , blood urine sample do get heart kidney function well research echo . After enrollment , study last twelve week . There one week visit outpatient set get blood draw 6 week visit outpatient set get blood draw , 24 hour urine collection resupply study medication . There one week visit outpatient set get blood draw 6 week visit outpatient set get blood draw , 24 hour urine collection resupply study medication .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Subjects ejection fraction le 45 % No clinical sign symptom congestive heart failure Ability walk minimal distance &gt; 450 meter 6minute walk . If subject able walk 450 meter due pain hip knee fatigue shortness breath , still qualify protocol . The subject stable dos angiotensin convert enzyme ( ACE ) inhibitor two week prior active study date . Therapy vasodilator , betareceptor antagonist , digoxin antiarrhythmic medication allow , however , medication must stable dos two week prior study date . Exclusion criterion : Myocardial infarction within 3 month screen Unstable angina within 14 day screen , evidence myocardial ischemia Significant valvular stenosis , hypertrophic , restrictive obstructive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , biopsy proven active myocarditis Severe congenital heart disease Sustained ventricular tachycardia ventricular fibrillation within 14 day screen Second third degree heart block without permanent cardiac pacemaker Stroke within 3 month screen , evidence significantly compromised central nervous system ( CNS ) perfusion Total bilirubin &gt; 1.5 mg/dL liver enzymes &gt; 1.5 time upper limit normal Serum creatinine &gt; 3.0 mg/dL Serum sodium &lt; 125 milliequivalent ( mEq ) /dL &gt; 160 mEq/dL Serum potassium &lt; 3.5 mEq/dL &gt; 5.0 mEq/dL change 5.3 Serum digoxin level &gt; 2.0 ng/ml Systolic pressure &lt; 85 mmHg Hemoglobin &lt; 10 gm/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>